Nothing Special   »   [go: up one dir, main page]

ATE437889T1 - Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration - Google Patents

Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration

Info

Publication number
ATE437889T1
ATE437889T1 AT05026397T AT05026397T ATE437889T1 AT E437889 T1 ATE437889 T1 AT E437889T1 AT 05026397 T AT05026397 T AT 05026397T AT 05026397 T AT05026397 T AT 05026397T AT E437889 T1 ATE437889 T1 AT E437889T1
Authority
AT
Austria
Prior art keywords
gpi
cells
tissue regeneration
tumour
chemokine
Prior art date
Application number
AT05026397T
Other languages
English (en)
Inventor
Ralf Prof Dr Huss
Peter Nelson
Hermann-Josef Prof Dr Groene
Original Assignee
Apceth Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth Gmbh & Co Kg filed Critical Apceth Gmbh & Co Kg
Application granted granted Critical
Publication of ATE437889T1 publication Critical patent/ATE437889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05026397T 2005-12-02 2005-12-02 Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration ATE437889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05026397A EP1792914B1 (de) 2005-12-02 2005-12-02 Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration

Publications (1)

Publication Number Publication Date
ATE437889T1 true ATE437889T1 (de) 2009-08-15

Family

ID=36047948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05026397T ATE437889T1 (de) 2005-12-02 2005-12-02 Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration

Country Status (7)

Country Link
US (1) US20120208769A1 (de)
EP (1) EP1792914B1 (de)
AT (1) ATE437889T1 (de)
AU (1) AU2006319440B2 (de)
CA (1) CA2631587C (de)
DE (1) DE602005015733D1 (de)
WO (1) WO2007062844A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014382A2 (en) * 2007-07-23 2009-01-29 Postech Academy-Industry Foundation Cxcl11 adjuvant compositions and uses thereof
CN101654679B (zh) * 2009-04-16 2012-06-13 浙江省台州医院 一种抗肿瘤融合基因及其表达蛋白与应用
CN102221608A (zh) * 2011-04-06 2011-10-19 浙江大学医学院附属第一医院 一种抗体组合物及其应用
EP2858672B1 (de) * 2012-06-08 2018-04-04 Alkermes, Inc. Fusionspolypeptide mit mucin-domänen-polypeptidvernetzern
WO2016077249A1 (en) * 2014-11-10 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for expressing polypeptides on the surface of cells
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
DK3302527T3 (da) 2015-06-03 2020-03-30 Medical College Wisconsin Inc Manipuleret CCL20-låst-dimerpolypeptid
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
WO2021087839A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用
MX2022006206A (es) 2019-11-25 2022-09-09 Alkermes Inc Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) * 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
EP1427426A4 (de) * 2001-08-27 2005-05-11 Greenville Hospital System Gpi-verankerte zytokine
WO2007047578A2 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries

Also Published As

Publication number Publication date
CA2631587C (en) 2013-01-15
US20120208769A1 (en) 2012-08-16
AU2006319440B2 (en) 2012-02-09
CA2631587A1 (en) 2007-06-07
AU2006319440A1 (en) 2007-06-07
DE602005015733D1 (de) 2009-09-10
EP1792914B1 (de) 2009-07-29
EP1792914A1 (de) 2007-06-06
WO2007062844A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
ATE437889T1 (de) Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
EP3414260B1 (de) Zusammensetzungstherapie einschliesslich ein inflamatorisches immumozytokin und ein chimärartiges antigenrezeptor (car)-t-zell
CN108367071B (zh) 用于癌症免疫疗法的nkg2d-ig融合蛋白
Schwager et al. The immunocytokine L19–IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF
CN100457189C (zh) 细胞因子与肿瘤靶向蛋白的融合物
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
MD3423105T2 (ro) Conjugați anticorp-medicament pe bază de eribulină și metode de utilizare
AR065289A1 (es) Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple
AU2017219415A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
HRP20240362T1 (hr) Pripravci i postupci namijenjeni liječenju hematološkog raka, koji ciljaju na međudjelovanje između sirp-alfa i cd47
WO2006047603A3 (en) Ungulates with genetically modified immune systems
BR112012009973A2 (pt) promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue
IL297418B2 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
BR112018007982A2 (pt) composição, reação enzimática e método para preparar um copolímero de enxerto
ATE527998T1 (de) Illudin-analoga als krebsmittel
BRPI0513534A (pt) inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
AR040753A1 (es) Composiciones de deposito de polimeros multimodales injectables y usos de las mismas
BR112022006440A2 (pt) Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
BR112012010983A2 (pt) composições e métodos para a estimulação do crescimento de cabelos
PE20080523A1 (es) Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
MX2015016564A (es) Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
CN110996972A (zh) 用于癌症治疗的治疗性凋亡细胞
WO2011044443A3 (en) Matricryptic ecm peptides for tissue reconstruction

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties